SYSTEMIC LUPUS ERYTHEMATOSUS

Ongoing Trials
Mycophenolate vs Cyclophosphamide for Severe Lupus Nephritis: nvestigators at the Center for Glomerular Diseases are participating in a new multi-national randomized trial comparing the efficacy and safefy of Mycophenolate mofetil (Cellcept) versus IV cyclophosphamide (cytoxan) in inducing response and maintaining remission in severe lupus nephritis 

Rituximab for Proliferative Lupus Nephritis: Rituximab vs. placebo in patients treated with mycophenolate for diffuse proliferative lupus nephritis. 

Completed Studies and Trials
An FDA sponsored study examined 140 SLE patients with active kidney disease randomized to mycophenolate mofetil (cellcept) versus monthly pulse IV cyclophosphamide. Patients receiving mycophenolate had a greater number of complete and partial remissions with greater tolerability than cyclophosphamide in an intention to treat analysis (Ginzler EM, Appel G et al. N Engl J Med. 2005 Nov 24;353(21):2219-28.) 
Other recent publications on SLE supported in part by the Glomerular Institute:

Zimmerman R, Radhakrishnan J,Valeri A, Appel GB. Newer treatments of lupus nephritis. Ann Rev Med.52:63-78, 2001.

Appel GB. Renal Vascular Lesions in SLE. Chapter 9:241-262, in Lupus Nephritis edited by E. Lewis - Oxford U. Press NY 1999.

Seliger S, Barr RG, Appel GB, Zuniga R, D'Agati V, Salmon J, Radhakrishnan J. Prognosis in Proliferative Lupus Nephritis: The role of socioeconomic status and race/ethnicity.Nephrol Dial Transplant. 2003 Oct;18(10):2039-46.

Dube GK, Markowitz GS, Radhakrishnan J, Appel GB, D'Agati VD. Minimal change disease in systemic lupus. Clin Nephrol.57: 120-127, 2002.

BACK